<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="240">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158023</url>
  </required_header>
  <id_info>
    <org_study_id>ASLAN004-003</org_study_id>
    <nct_id>NCT05158023</nct_id>
  </id_info>
  <brief_title>Phase 2b Study of Efficacy and Safety of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aslan Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aslan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients&#xD;
      with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This&#xD;
      study will have 5 treatment arms (4 active and 1 placebo).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from Baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving validated Investigator's Global Assessment (vIGA) response of 0 or 1 [5 point scale]</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with EASI 50, 75 and 90</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with EASI &lt;7</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in EASI score from Baseline over time</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent change in Pruritus Numerical Rating Scale (P-NRS) over time</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a 4-point reduction in P-NRS</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Surface Area (BSA) affected with AD</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcomes (PROs) over time</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent change in sleep NRS over time</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">295</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo q2w - placebo injections at Baseline and Week 1, then every 2 weeks (q2w) to Week 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASLAN004 300 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 300mg (q2w) to Week 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASLAN004 400 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 400mg (q2w) to Week 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg or alternating placebo (q2W) to Week 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASLAN004 and Placebo</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients with a clinical diagnosis of AD for at least 1 year;&#xD;
&#xD;
          2. vIGA score of ≥3 at Screening and Baseline;&#xD;
&#xD;
          3. ≥10% BSA of AD involvement at Screening and Baseline;&#xD;
&#xD;
          4. EASI score ≥16 at Screening and Baseline;&#xD;
&#xD;
          5. History of inadequate response to treatment with topical corticosteroids (TCS) or&#xD;
             topical calcineurin inhibitors (TCI);&#xD;
&#xD;
          6. Twice daily application of a consistent amount of topical emollient for at least 7&#xD;
             days prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment at any time prior to randomization with monoclonal antibody /&#xD;
             biologic therapeutic agents as follows;&#xD;
&#xD;
               1. Prior exposure to dupilumab (Dupixent®) which was discontinued due to lack of&#xD;
                  efficacy, loss of response, or adverse event;&#xD;
&#xD;
               2. Investigational or approved agents targeting interleukins IL-4 or IL-13 ligands&#xD;
                  or receptors of IL-4 or IL-13, including but not limited to lebrikizumab,&#xD;
                  tralokinumab or ASLAN004;&#xD;
&#xD;
               3. Other investigational or approved biologic drug within 16 weeks or within 5&#xD;
                  half-lives (if known), whichever is longer, prior to the Baseline visit;&#xD;
&#xD;
               4. Cell-depleting biologics, including, but not limited to, rituximab within 6&#xD;
                  months prior to the Baseline visit;&#xD;
&#xD;
          2. Immunosuppressive/immunomodulating drugs, systemic therapies or phototherapy within 4&#xD;
             weeks prior to randomization;&#xD;
&#xD;
          3. Treatment with leukotriene inhibitors within 4 weeks prior to randomization;&#xD;
&#xD;
          4. Treatment with topical therapies (including TCS, TCI, topical phosphodiesterase&#xD;
             inhibitors, topical JAK inhibitors) or prescription moisturizers, within 1 week prior&#xD;
             to randomization;&#xD;
&#xD;
          5. Inadequate organ function, abnormal lab result, uncontrolled blood pressure or other&#xD;
             health condition considered clinically significant by the investigator at the&#xD;
             Screening visit;&#xD;
&#xD;
          6. History of HIV, Hepatitis B, Hepatitis C or active/latent Tuberculosis infection;&#xD;
&#xD;
          7. History of immunosuppression including history of invasive opportunistic infections;&#xD;
&#xD;
          8. Treatment with live attenuated vaccine within 8 weeks prior to randomization;&#xD;
&#xD;
          9. Parasitic infection within 4 weeks prior to randomization travel within 3 months prior&#xD;
             to randomization to areas of high parasitic exposure;&#xD;
&#xD;
         10. Have skin comorbidities that in the opinion of the Investigator may interfere with&#xD;
             study assessments&#xD;
&#xD;
         11. Pregnant or breastfeeding women;&#xD;
&#xD;
         12. Patients unwilling to use adequate birth.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Kobayashi, MD, FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>Aslan Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ASLAN Pharmaceuticals</last_name>
    <phone>+6562224235</phone>
    <email>contact@aslanpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ASLAN Investigative Site</name>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <email>contact@aslanpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASLAN Investigative Site</name>
      <address>
        <city>Carlton</city>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <email>contact@aslanpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASLAN Investigative Site</name>
      <address>
        <city>Fremantle</city>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <email>contact@aslanpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASLAN Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>contact@aslanpharma.com</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASLAN Investigative Site</name>
      <address>
        <city>Victoria Park</city>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <email>contact@aslanpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASLAN Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <email>contact@aslanpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASLAN Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <contact>
      <email>contact@aslanpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASLAN Investigative Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <email>contact@aslanpharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <keyword>IL-13</keyword>
  <keyword>ASLAN004</keyword>
  <keyword>IL-13Rα1</keyword>
  <keyword>Eczema</keyword>
  <keyword>Anti-IL-13Rα1</keyword>
  <keyword>atopic eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

